痛风患者慢性肾脏病与内脏脂肪及皮下脂肪葡萄糖摄取相关代谢活性增加的相关性
该研究利用加州大学圣地亚哥分校患者数据库构建接受PET/CT检查的队列,共纳入221例患者,其中120例诊断为痛风,评估内脏脂肪组织(VAT)和皮下脂肪组织(SAT)的18F-氟脱氧葡萄糖PET标准化摄取值。经逆概率加权调整后,痛风患者VAT和SAT平均SUVmax均较高;在合并CKD≥3期的痛风患者中,较高的VAT和SAT平均SUVmax与PET/CT后5年内eGFR下降相关。作者认为痛风患者VAT和SAT葡萄糖摄取相关代谢活性升高,可能促进痛风合并CKD患者的CKD进展。
要点
- 痛风患者经逆概率加权调整后VAT平均SUVmax较高(β=0.09,95%CI 0.04-0.15)。
- 痛风患者经逆概率加权调整后SAT平均SUVmax较高(β=0.06,95%CI 0.01-0.12)。
- 合并CKD≥3期的痛风患者中,VAT和SAT平均SUVmax较高与PET/CT后5年内eGFR下降相关。
核心结论
- 痛风患者VAT和SAT葡萄糖摄取相关代谢活性升高,可能促进痛风合并CKD患者的CKD进展。
研究设计与样本
- 利用加州大学圣地亚哥分校患者数据库的国际疾病分类第十版编码识别痛风患者和对照,形成接受PET/CT检查的队列,共221例,其中120例诊断为痛风。
- 采用逆概率加权分析调整潜在混杂因素,并采用多变量线性回归分析PET/CT后估算肾小球滤过率(eGFR)的变化。
主要发现
- 经逆概率加权调整后,痛风患者VAT平均SUVmax较高(β=0.09,95%CI 0.04-0.15)。
- 经逆概率加权调整后,痛风患者SAT平均SUVmax较高(β=0.06,95%CI 0.01-0.12)。
- 在合并CKD≥3期的痛风患者中,较高的VAT平均SUVmax与PET/CT后5年内eGFR下降相关(β=-1.76,95%CI -3.50至-0.01)。
- 在合并CKD≥3期的痛风患者中,较高的SAT平均SUVmax与PET/CT后5年内eGFR下降相关(β=-2.97,95%CI -5.61至-0.32)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluate the 18F-fluorodeoxyglucose positron emission tomography (PET) standardized uptake value (SUV) by PET/computed tomography (CT) scans in visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) in patients with and without gout. Additionally, we investigate whether glucose uptake in these tissues predicts the progression of chronic kidney disease (CKD). METHODS: We used International Classification of Diseases, Tenth Revision codes from the University of California San Diego patient database to identify patients with gout and controls, forming a cohort of individuals who underwent PET/CT scans. The mean VAT and SAT maximum SUV (SUVmax) were measured using PET/CT scans and adjusted for potential confounders using inverse probability of weighting analysis. We also employed multivariable linear regression to analyze changes in estimated glomerular filtration rate (eGFR) after PET/CT scans. RESULTS: The study included 221 patients, with 120 diagnosed with gout. After the inverse probability of weighting adjustment, the mean VAT and SAT SUVmax were higher in patients with gout (mean VAT SUVmax: β = 0.09, 95% confidence interval [CI] 0.04-0.15; mean SAT SUVmax: β = 0.06, 95% CI 0.01-0.12). Additionally, in patients with gout with CKD stage ≥3, higher mean VAT and SAT SUVmax were associated with decreased eGFR in the 5 years following PET/CT scans (mean VAT SUVmax: β = -1.76, 95% CI -3.50 to -0.01; mean SAT SUVmax: β = -2.97, 95% CI -5.61 to -0.32). CONCLUSION: Elevated glucose uptake-associated metabolic activity in both VAT and SAT was observed in patients with gout, which may contribute to CKD progression among patients with both gout and CKD.
引用
- Kaneshita S, Fukui S, Niku S, et al. Association of Chronic Kidney Disease With Increased Glucose Uptake-Associated Metabolic Activity of Visceral Adipose and Subcutaneous Adipose Tissue in Patients With Gout. Arthritis Care Res (Hoboken). 2025. PMID: 40176415. doi:10.1002/acr.25540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。